Skip to main content
. Author manuscript; available in PMC: 2015 Oct 19.
Published in final edited form as: Pediatr Blood Cancer. 2012 Dec 19;60(6):1009–1015. doi: 10.1002/pbc.24429

TABLE 1.

Pathways That Can Be Therapeutically Targeted in Ewing Sarcoma and Osteosarcoma

Molecular
target
Example of
inhibitory drug
Global metastases processes
   Apoptosis/Anoikis AKT MK-2206
mTOR Temsirolimus
   Angiogenesis VEGF Bevacizumab
VEGFR Sorafenib
Preferential OS processes
   Invasion c-SRC Saracatinib
   Migration HGF/c-MET PF-02341066
   Proliferation/survival IGF-1R Cixutumumab